Breast Cancer Research and Treatment **53**: 291-292, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 53

Akewanlop C 199
Allred DC 51
Altaras MM 255
Ao X 217
Ashley SE 51
Asou H 113
Azagra P 105

Bando E 97
Barsky SH 263
Bennett CF 41
Bernheim J 255
Bertelli G 145
Beyth Y 255
Binderup L 113
Bonadonna G 209
Bonilla F 9
Borgen PI 87
Boyd J 87
Brambilla C 209
Brudin L 1

Cao J-N 279
Carozzo L 145
Cho SK 113
Ciolino HP 229
Cline JM 61
Cohen I 255
Cordoba M 255
Costa A 145

Dahiya R 185
Daschner PJ 229
de Paz L 105
Dearing SJ 167
Decensi A 145
Deguchi S 33
Demicheli R 209
Deo YM 199
Dini D 145
Dominguez G 9
Dowsett M 51
Du X 137

España P 9

Federici MG 87
Ferrari L 209
Figer A 255
Fishman A 255
Flex D 255
Fontana JA 263
Fontana V 145
Franklin B 87
Freeman JL 137
Fujii A 19

Gallego I 9
Gao T-W 279
Garcia JM 9
Garcia-Conde J 105
Giuliano AE 279
Goel V 69
Gonzalez R 9
Goodwin JS 137
Gozza A 145
Grill C 217

Haga S 177
Han Q-X 263
Hayes DF 199
Hennig EM 121
Holm R 121

Imamura H 177
Inano H 153
Irie RF 279
Isaksson E 61
Ishii N 19

Jiang Z-F 77
Joensuu H 161
Juan O 105

Kajiwara T 177
Kameoka S 19
Karr B 87

Kasajima T 19
Kato T 19
Kawahara F 97
Keler T 199
Kimura T 19
Kinoshita J 177
Kobayashi H 153
Koeffler HP 113
Koike M 113
Koshizuka K 113
Kumar R 41
Kvinnsland S 121

Lemon SJ 87
Li J 263
Lipton A 41
Liu X-Q 77
Liu X-W 77
Lluch A 105
Lynch HT 87
Lynch J 87

Mäenpää H 161
Makris A 51
Mandal M 41
Martínez-Agulló A 105
Marugán I 105
Miceli R 209
Milone S 145
Miraglia L 41
Miwa K 97
Miyaguni T 33
Moliterni A 209
Muto Y 33

Nakajima K 97
Nesland JM 121
Newcomb PA 271
Nishikawa T 19
Noguchi M 97
Nordenskjöld B 1

Ondrusek N 69

Onoda M 153
Ormerod MG 51

Palacios J 9
Pensa F 145
Perel E 255
Perhoniemi V 161
Plouzek CA 229
Powles TJ 51
Prósper F 105
Provencio M 9

Rhei E 87
Rock CL 241
Rubinsky B 185
Rude RK 113
Rui J 185
Russo IH 217
Russo J 217

Salven P 161
Saxe GA 241
Schottenfeld D 241
Severi G 145
Shao Z-M 263
Shapira J 255
Shen Z-Z 263
Shimizu T 177
Silva JM 9
Skoog L 61
Söderqvist G 61
Solomon C 271
Song S-T 77
Stephen T 113
Sundquist M 1
Suo Zh 121
Suzuki K 153

Tamamoto T 33
Tang Z-M 77
Tatsutani KN 185
Tepper R 255
Thoresen 121
Thorstenson S 1
Titley JC 51
Toda T 33
Tomita S 33
Tonami N 97
Torrisi R 145
Traverso A 145
Trott PA 51
Tsugawa K 97
Tykkä H 161

Uskokovic M 113

Valagussa P 209
von Schoultz B 61
von Schoultz E 61

Wakabayashi K 153
Walker RA 167
Wallace PK 199
Warner E 69
Watanabe M 199
Watanabe O 177
Watson P 87
White E 271
Wicha MS 241
Wilking N 61
Witters L 41
Wu J 263

Xu J-M 77

Yamamoto K 19
Yeh GC 229
Yigael D 255
Yokoyama K 97

Zambetti M 209
Zhang J 77
Zhou L 77

Breast Cancer Research and Treatment **53**: 293-296, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 53

adhesion molecules
CD44 variant exon v7-v8 and lymphatic metastasis 177-183
adjuvant therapy
analysis of recurrence times — evidence for "cures" 209-215
angiogenesis
comparison of microvessel density methodologies in predicting survival 19-32
elevated serum VEGF with metastatic breast cancer 161-166
antibody-dependent cellular cytoxicity
induced by bispecific anti-HER2/anti-Fcγ-receptor antibody 199-207
antigens
breast tumor-associated epitope identified as retinoblastoma binding protein 1 279-290
antisense
EGFR antisense oligonucleotides and growth inhibition in cancer cell lines 41-50
AP-1
increased c-*jun* and c-*fos* mRNA, AP-1 activity, mediate increased *MDR1* drug resistance in MCF-7 229-240
apoptosis
induction by neo-adjuvant chemotherapy correlated with response 263-269
axillary dissection
declining use in patients with early stage breast cancer 137-144
sentinel node biopsy — review of methods and reliability 97-104

bispecific antibody
cell killing induced by bispecific anti-HER2/anti-Fcγ-receptor antibody 199-207
BNX triple immunodeficient mice
in xenograft model treated with paclitaxel plus vitamin D_3 analogs 113-120
bone mineral density
no change with fenretinide treatment 145-151
BRCA genes
LOH for BRCA1 and BRCA2 associated with poor prognostic factors 9-18
breast epithelial differentiation
cells with ERα and PgR are not the proliferating cells 217-227

CD44 antigen
variant exon v7-v8 and lymphatic metastasis 177-188
cervical neoplasia
and HPV 16 in second primary breast cancers 121-135
chemoprevention
no change in bone mineral density, trend to increased bone resorption markers, with 4-HPR treatment 145-151
chemotherapy
analysis of recurrence times ± adjuvant CMF — evidence for "cures" 209-215
MTT *in vitro* chemosensitivity assay in predicting response 77-85
paclitaxel additive with vitamin D_3 analogs in xenograft model 113-120
response to neo-adjuvant chemotherapy correlated with induced apoptosis 263-269
colorectal cancer
increased risk 5 or more years after breast cancer diagnosis in patients receiving tamoxifen 271-277
cryosurgery
effects of thermal regimen variables 185-192
cynomolgus macaques
p53 changes during HRT or tamoxifen treatment in macaque breast and endometrium 61-67

diabetes mellitus
and endometrial pathologies in tamoxifen-treated patients 255-262
diet
pre-diagnosis dietary factors, oral contraceptive use, and risk of recurrence 241-253
diethylstilbestrol (DES)
tumor promotion by DES, not progestin, after γ-irradiation to lactating rats 153-160

drug resistance
increased c-*jun* and c-*fos* mRNA, AP-1 activity, mediate increased *MDR1* drug resistance in MCF-7 229-240
MTT *in vitro* chemosensitivity assay in predicting response 77-85

endometrial cancer
increased after hormone therapy (mainly tamoxifen) — SEER data 271-277
endometrial pathologies
association with cumulative tamoxifen dose 255-262
epidermal growth factor receptor (EGFR)
antisense oligonucleotides and growth inhibition in cancer cell lines 41-50
mRNA and protein incidence in breast cancers, correlated with lack of ER 167-176
estrogen receptor
cells with ERα and PgR are not the proliferating cells in normal developing breast 217-227
inverse correlation with EGFR 167-176
estrogen receptor
reduction in FNA's during neoadjuvant therapy 51-60

family history
development of a breast cancer and heredity knowledge scale questionnaire 69-76
fat and energy intake
pre-diagnosis, and risk of recurrence 241-253
Fcγ receptor
target for cell killing induced by bispecific anti-HER2/anti-Fcγ-receptor antibody 199-207
fenretinide (4-HPR)
no change in bone mineral density, trend to increased bone resorption markers, with 4-HPR treatment 145-151
fine needle aspirates (FNA's)
changes in molecular markers during neoadjuvant therapy
flow cytometry
in measurement of antibody-dependent cellular phagocytosis 199-207

genetics
development of a breast cancer and heredity knowledge scale questionnaire 69-76
genetics *(continued)*
germline mutation of *MLH1* gene in a male breast cancer in an HNPCC family 87-91

HER-2/*neu*
target for cell killing induced by bispecific anti-HER2/anti-Fcγ-receptor antibody 199-207
hereditary breast cancer
development of a breast cancer and heredity knowledge scale questionnaire 69-76
hereditary nonpolyposis colorectal cancer syndrome (HNPCC)
and occurrence of male breast cancer 87-91
histopathologic grade
and the Nottingham Prognostic Index in a Swedish population 1-8
hormone replacement therapy (HRT)
and endometrial pathologies in tamoxifen-treated patients 255-262
p53 changes during HRT or tamoxifen treatment in macaque breast and endometrium 61-67
human papillomavirus 16 (HPV 16)
HPV 16 in breast cancers of women with HPV-16-positive cervical neoplasia 121-135

immunogenicity
breast tumor-associated peptide epitope identified as retinoblastoma binding protein 1 279-290
immunotherapy
cell killing induced by bispecific anti-HER2/anti-Fcγ-receptor antibody 199-207
isolated recurrence (Stage IV-NED)
importance of systemic therapy; prognostic factors 105-112

loss of heterozygosity (LOH)
for BRCA1 and BRCA2, associated with poor prognostic factors 9-18
lymphatic metastasis
enhanced by CD44 variant v7-v8
lymphoscintigraphy
in sentinel node biopsy — review 97-104

male breast cancer
occurrence in hereditary nonpolyposis colorectal cancer syndrome family 87-91

mammary gland development
cells with ERα and PgR are not the proliferating cells 217-227
mammary tumorigenesis
promotion by estrogen, not progestin, after γ-radiation to lactating rats 153-160
MCF-7 human breast cancer cells
increased c-*jun* and c-*fos* mRNA, AP-1 activity, mediate increased *MDR1* drug resistance 229-240
metastasis
CD44 variant exon v7-v8 and lymphatic adhesion/metastasis 177-188
microsatellite instability
incidence in breast cancer, associated with poor prognostic factors 33-40
microsatellites
and LOH determinations for BRCA1 and BRCA2 9-18
microvessel density
comparison of three methodologies in predicting survival 19-32
mismatch repair gene *MLH1*
germline mutation in a male breast cancer in an HNPCC family 87-91
MTT *in vitro* chemosensitivity assay
in directing chemotherapy for advanced breast cancer 77-85
multidrug resistance
increased c-*jun* and c-*fos* mRNA, AP-1 activity, mediate increased *MDR1* drug resistance in MCF-7 229-240

neo-adjuvant chemotherapy
changes in molecular markers in FNA's 51-60
response correlated with induced apoptotic index 263-269
neovascularization
see angiogenesis
Nottingham Prognostic Index
applied to a Swedish population 1-8

oral contraceptives
pre-diagnosis dietary factors, oral contraceptive use, and risk of recurrence 241-253

p53
changes during HRT or tamoxifen treatment in macaque breast and endometrium 61-67
paclitaxel
additive with vitamin D_3 analogs in treatment of xenograft model 113-120
papillomavirus
HPV 16 in breast cancers of women with HPV-16-positive cervical neoplasia 121-135
patient management
declining use of axillary dissection in subsets of early stage breast cancer 137-144
peptides
breast tumor-associated peptide epitope identified as retinoblastoma binding protein 1 279-290
prediction of chemotherapy response
MTT *in vitro* chemosensitivity assay in advanced breast cancer 77-85
primary medical treatment
see neoadjuvant therapy
progesterone receptor
cells with ERα and PgR are not the proliferating cells in normal developing breast 217-227
prognostic factors
associated with LOH for BRCA1 and BRCA2 9-18
for patients with isolated recurrence (Stage IV-NED) 105-112
microsatellite instability associated with other factors 33-40
microvessel density — three methodologies vs. other factors and survival 19-32
Nottingham Index in a Swedish population 1-8
pre-diagnosis dietary factors, oral contraceptive use, and risk of recurrence 241-253
proliferation
changes in SPF and Ki67 in FNA's during neo-adjuvant therapy 51-60
proliferation in developing mammary gland
proliferating cells (TLI or Ki67) do not contain the ERα or PgR 217-227
promotion
see tumor promotion

recurrence times
analysis ± adjuvant CMF — evidence for "cures" 209-215
retinoblastoma binding protein 1
a new breast tumor associated epitope 279-290

retinoids
no change in bone mineral density, trend to increased bone resorption markers, with fenretinide treatment 145-151
risk factors
pre-diagnosis dietary factors, oral contraceptive use, and risk of recurrence 241-253

sentinel node biopsy
review of methods and reliability 97-104
serum markers
elevated serum VEGF with metastatic breast cancer 161-166
retinoblastoma binding protein 1 antibody titers 279-290
Stage IV-NED isolated recurrences
importance of systemic therapy; prognostic factors 105-112
surgical oncology
effects of thermal regimen variables in cryosurgery 185-192

tamoxifen
cumulative dose associated with endometrial pathologies 255-262
tamoxifen *(continued)*
decreased contralateral breast cancer and increased endometrial cancer — SEER data 271-277
increased risk of colorectal cancer 5 or more years after diagnosis 271-277
p53 changes during HRT or tamoxifen treatment in macaque breast and endometrium 61-67
Taxol
see paclitaxel
transforming growth factor β (TGFβ) receptors
no TGFβ receptor type II mutations in 101 breast tumors 33-40
tumor progression
and elevation of serum VEGF 161-166
tumor promotion
by estrogen, not progestin, after γ-radiation to lactating rats 153-160

vascular endothelial growth factor (VEGF)
elevated serum levels with metastatic breast cancer 161-166
vitamin D_3 analogs
additive with paclitaxel treatment in xenograft model 113-120